Akebia Therapeutics Inc AKBA:NASDAQ

Last Price$2.54NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/06/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$2.52 (3)
Ask (Size)$2.58 (2)
Day Low / HighN/A - N/A
Volume2.7 M
 

View Biotechnology IndustryPeer Comparison as of 12/06/2021

 

Akebia Therapeutics Inc ( NASDAQ )

Price: $2.54
Change: +0.02 (0.79%)
Volume: 2.7 M
4:00PM ET 12/06/2021
 
 

Mersana Therapeutics Inc ( NASDAQ )

Price: $6.07
Change: -0.10 (1.62%)
Volume: 742.0 K
4:00PM ET 12/06/2021
 
 

Verastem Inc ( NASDAQ )

Price: $2.38
Change: -0.04 (1.65%)
Volume: 1.4 M
4:00PM ET 12/06/2021
 
 

Curis Inc ( NASDAQ )

Price: $4.71
Change: +0.22 (4.90%)
Volume: 1.3 M
4:15PM ET 12/06/2021
 
 

Omeros Corp ( NASDAQ )

Price: $6.84
Change: -0.03 (0.44%)
Volume: 320.00
4:00PM ET 12/06/2021
 

Read more news Recent News

--HC Wainwright Adjusts Akebia Therapeutics' Price Target to $10 From $6, Keeps Buy Rating
9:06AM ET 11/11/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Akebia Therapeutics Narrows Q3 Net Loss, Revenue Declines; Shares Fall
11:47AM ET 11/04/2021 MT Newswires

Akebia Therapeutics (AKBA) reported a Q3 net loss Thursday of $0.34 per share, narrowing from a loss of $0.42 per share a year earlier. Analysts polled by...

-- Earnings Flash (AKBA) AKEBIA THERAPEUTICS Posts Q3 Revenue $48.8M, vs. Street Est of $51.4M
8:06AM ET 11/04/2021 MT Newswires

...

Akebia Says Partner Otsuka Files Initial MAA for Vadadustat with European Medicines Agency
3:52PM ET 10/29/2021 MT Newswires

Akebia Therapeutics (AKBA) said Friday that its collaborator Otsuka Pharmaceutical's Netherlands unit has filed an initial marketing authorization to the...

Company Profile

Business DescriptionAkebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA. View company web site for more details
Address245 First Street
Cambridge, Massachusetts 02142
Phone+1.617.871.2098
Number of Employees325
Recent SEC Filing11/04/20218-K
President, Chief Executive Officer & DirectorJohn P. Butler
Chief Operating Officer & Senior Vice PresidentMichel Dahan
Chief Financial Officer, Treasurer & Senior VPDavid A. Spellman
Chief Medical Officer & Senior Vice PresidentSteven K. Burke

Company Highlights

Price Open$2.52
Previous Close$2.54
52 Week Range$2.35 - 5.14
Market Capitalization$444.4 M
Shares Outstanding175.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.89
Beta vs. S&P 500N/A
Revenue$207.7 M
Net Profit Margin-142.00%
Return on Equity-154.75%

Analyst Ratings as of 11/20/2021

Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset